Marta Ortega-Valle - 02 Feb 2022 Form 4 Insider Report for GreenLight Biosciences Holdings, PBC (GRNA)

Role
Chief Business Officer
Signature
/s/ David Kennedy, Attorney-in-fact
Issuer symbol
GRNA
Transactions as of
02 Feb 2022
Net transactions value
$0
Form type
4
Filing time
04 Feb 2022, 18:28:52 UTC
Next filing
08 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GRNA Stock Option (Right to Buy) Award +29,798 29,798 02 Feb 2022 Common Stock 29,798 $0.2400 Direct F1, F2
transaction GRNA Stock Option (Right to Buy) Award +105,266 105,266 02 Feb 2022 Common Stock 105,266 $0.2800 Direct F2, F3
transaction GRNA Stock Option (Right to Buy) Award +106,098 106,098 02 Feb 2022 Common Stock 106,098 $0.3500 Direct F2, F4
transaction GRNA Stock Option (Right to Buy) Award +247,727 247,727 02 Feb 2022 Common Stock 247,727 $0.9800 Direct F2, F5
transaction GRNA Stock Option (Right to Buy) Award +259,584 259,584 02 Feb 2022 Common Stock 259,584 $0.9800 Direct F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 100% of the shares subject to this option are fully vested and exercisable.
F2 This option was issued pursuant to the terms of a business combination agreement involving the Issuer and GreenLight Biosciences, Inc. in exchange for a comparable option previously issued by such company.
F3 100% of the shares subject to this option are fully vested and exercisable.
F4 100% of the shares subject to this option are fully vested and exercisable.
F5 20% of the shares underlying the option vested or shall vest on September 24, 2021 and the remainder of the shares vested or shall vest in 48 equal monthly installments thereafter, starting October 24, 2021.
F6 25% of the shares underlying the option vested or shall vest on December 1, 2021 and the remainder of the shares vested or shall vest in 36 equal monthly installments thereafter, starting January 1, 2022.